Anderson Forschung to Develop Assay for Biomarker Quantitation for BiOasis | GenomeWeb
NEW YORK (GenomeWeb News) – BiOasis said today that it has tapped the Anderson Forschung Group to develop a new proteomics assay for diagnosing Alzheimer’s disease.
 
Under the agreement, Anderson Forschung will develop an assay using a technique called Stable Isotope Standards and Capture by Anti-Peptide Antibodies, a proteomics platform aimed at biomarker quantification and qualification.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.